Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3131
Source ID: NCT00143520
Associated Drug: Rivoglitazone
Title: Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes
Interventions: DRUG: Rivoglitazone|DRUG: Pioglitazone|DRUG: Placebo
Outcome Measures: Primary: Change in HbA1c | Secondary: FPG, Lipids, hsCRP, Adiponectin
Sponsor/Collaborators: Sponsor: Daiichi Sankyo
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2|PHASE3
Enrollment: 441
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2004-12
Completion Date: 2005-12
Results First Posted:
Last Update Posted: 2021-05-10
Locations: Birmingham, Alabama, United States|Columbiana, Alabama, United States|Huntsville, Alabama, United States|Muscle Shoals, Alabama, United States|Hot Springs, Arkansas, United States|Jonesboro, Arkansas, United States|Little Rock, Arkansas, United States|Searcy, Arkansas, United States|Sherwood, Arkansas, United States|Los Angeles, California, United States|Moreno Valley, California, United States|Sacramento, California, United States|San Diego, California, United States|San Mateo, California, United States|Santa Monica, California, United States|Torrance, California, United States|Vista, California, United States|West Hills, California, United States|Newark, Delaware, United States|Clearwater, Florida, United States|Cocoa Beach, Florida, United States|Jupiter, Florida, United States|Largo, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Palm Harbor, Florida, United States|Pembroke Pines, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Warner Robins, Georgia, United States|Chicago, Illinois, United States|Gurnee, Illinois, United States|Evansville, Indiana, United States|Lexington, Kentucky, United States|New Orleans, Louisiana, United States|Detroit, Michigan, United States|Livonia, Michigan, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Bozeman, Montana, United States|Butte, Montana, United States|Great Falls, Montana, United States|Voorhees, New Jersey, United States|Rochester, New York, United States|Charlotte, North Carolina, United States|Statesville, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Marion, Ohio, United States|Clinton, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Medford, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Charleston, South Carolina, United States|Simpsonville, South Carolina, United States|Bristol, Tennessee, United States|Carrollton, Texas, United States|Conroe, Texas, United States|Houston, Texas, United States|Midland, Texas, United States|San Antonio, Texas, United States|Spring, Texas, United States|Sugar Land, Texas, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Virginia Beach, Virginia, United States|Lakewood, Washington, United States|Olympia, Washington, United States|Renton, Washington, United States|Spokane, Washington, United States|Milwaukee, Wisconsin, United States
URL: https://clinicaltrials.gov/show/NCT00143520

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D336 Pioglitazone small molecule DB01132 Details